JP2021518104A5 - - Google Patents

Info

Publication number
JP2021518104A5
JP2021518104A5 JP2020548722A JP2020548722A JP2021518104A5 JP 2021518104 A5 JP2021518104 A5 JP 2021518104A5 JP 2020548722 A JP2020548722 A JP 2020548722A JP 2020548722 A JP2020548722 A JP 2020548722A JP 2021518104 A5 JP2021518104 A5 JP 2021518104A5
Authority
JP
Japan
Prior art keywords
sequence
seq
region
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020548722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022272 external-priority patent/WO2019178356A1/en
Publication of JP2021518104A publication Critical patent/JP2021518104A/ja
Publication of JP2021518104A5 publication Critical patent/JP2021518104A5/ja
Priority to JP2024018466A priority Critical patent/JP2024054286A/ja
Priority to JP2026076105A priority patent/JP2026119147A/ja
Withdrawn legal-status Critical Current

Links

JP2020548722A 2018-03-14 2019-03-14 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法 Withdrawn JP2021518104A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024018466A JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
JP2026076105A JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643040P 2018-03-14 2018-03-14
US62/643,040 2018-03-14
US201862657151P 2018-04-13 2018-04-13
US62/657,151 2018-04-13
PCT/US2019/022272 WO2019178356A1 (en) 2018-03-14 2019-03-14 Engineered cells, t cell immune modulating antibodies and methods for using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018466A Division JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2021518104A JP2021518104A (ja) 2021-08-02
JP2021518104A5 true JP2021518104A5 (cg-RX-API-DMAC7.html) 2022-04-05

Family

ID=67908100

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020548722A Withdrawn JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
JP2026076105A Pending JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法
JP2026076105A Pending JP2026119147A (ja) 2018-03-14 2026-04-30 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法

Country Status (5)

Country Link
US (2) US12258378B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765070A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021518104A (cg-RX-API-DMAC7.html)
AU (2) AU2019235900B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019178356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7649239B2 (ja) 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法
CA3141926A1 (en) 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
CA3159308A1 (en) * 2019-12-02 2021-06-10 Wayne A. Marasco Antibodies against pd-l1 and methods of use thereof
JP7752621B2 (ja) * 2020-02-17 2025-10-10 ミルテニー バイオテック ベー.フェー. ウント コー. カー・ゲー 腫瘍微小環境細胞に対するキメラ抗原受容体(car)を有するパーソナライズされた細胞を提供する方法
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
WO2023147776A1 (en) * 2022-02-07 2023-08-10 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
CN114686592B (zh) * 2022-05-30 2022-09-09 广东忠信生物科技有限公司 一种多类型靶标联合检测的试剂盒及制备方法、使用方法
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
CN118252937B (zh) * 2024-04-07 2024-10-22 中山大学 Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009134962A2 (en) * 2008-04-30 2009-11-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
EP3957653A1 (en) 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012143524A2 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9598496B2 (en) * 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP4292657A3 (en) 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
EP3119804A2 (en) 2014-03-19 2017-01-25 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015164865A1 (en) 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016033547A1 (en) * 2014-08-29 2016-03-03 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and oprl
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
EP3029067A1 (en) * 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
RU2017125531A (ru) 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA2998589A1 (en) * 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.

Similar Documents

Publication Publication Date Title
Lu et al. Development of therapeutic antibodies for the treatment of diseases
JP2022512653A5 (cg-RX-API-DMAC7.html)
JP2024054286A5 (cg-RX-API-DMAC7.html)
JP2022512684A5 (cg-RX-API-DMAC7.html)
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2022513668A5 (cg-RX-API-DMAC7.html)
JP2020526211A5 (cg-RX-API-DMAC7.html)
US20200332015A1 (en) Antibodies targeting cd137 and methods of use thereof
JP2018533371A5 (cg-RX-API-DMAC7.html)
JP2022512917A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
KR20190028716A (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
IL295381A (en) bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
CN107074950A (zh) 使用抗nkg2a抗体的治疗方案
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2022514734A5 (cg-RX-API-DMAC7.html)
JP2022544825A5 (cg-RX-API-DMAC7.html)
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
WO2020200256A1 (zh) 一种融合蛋白及其用途
WO2021186056A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
TW202011989A (zh) 癌症之治療
JP2024541476A5 (cg-RX-API-DMAC7.html)
JP2025530888A5 (cg-RX-API-DMAC7.html)